Compare WEYS & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | OABI |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.9M | 294.3M |
| IPO Year | 1995 | 2021 |
| Metric | WEYS | OABI |
|---|---|---|
| Price | $46.24 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 19.0K | ★ 594.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $276,169,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $22.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.25 | $1.32 |
| 52 Week High | $48.68 | $3.64 |
| Indicator | WEYS | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 73.18 | 83.83 |
| Support Level | $30.98 | $1.84 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.88 | 0.21 |
| MACD | 0.59 | 0.17 |
| Stochastic Oscillator | 72.62 | 87.90 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, South Africa, and Australia.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.